SCHEMBL13624223

SCHEMBL13624223

CCOC(=O)C1(C)CCN(c2ccc(N)cc2)CC1

nearest known ligand 0.49

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAPT P10636 5/20 0.49
GFER P55789 3/20 0.49
KDM4E B2RXH2 3/20 0.49
GAA P10253 3/20 0.49
SMN1; SMN2 Q16637 2/20 0.49
RAD52 P43351 1/20 0.49
CASP6 P55212 1/20 0.47
LMNA P02545 3/20 0.46
ALDH1A1 P00352 3/20 0.44
LGMN Q99538 2/20 0.43
OPRM1 P35372 5/20 0.43
OPRD1 P41143 3/20 0.43
OPRK1 P41145 3/20 0.43
SLC22A1 O15245 1/20 0.43
SLC6A4 P31645 1/20 0.43
ADRA1A P35348 1/20 0.43
KCNH2 Q12809 1/20 0.43
CYP1A2 P05177 1/20 0.43
CYP3A4 P08684 1/20 0.43
MAOA P21397 1/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL28704750 0.86 OPRM1 (0.55) MAPTGAALMNAALDH1A1OPRM1
SCHEMBL2946650 0.85 USP2 (0.48) MAPTKDM4EGAASMN1; SMN2LMNA
SCHEMBL981749 0.84 MAPT (0.44) MAPTKDM4EGAASMN1; SMN2LMNA
SCHEMBL3315322 0.83 CYP2C9 (0.51) KDM4ESMN1; SMN2ALDH1A1CYP1A2CYP3A4
SCHEMBL13624217 0.83 MAPT (0.67) MAPTSMN1; SMN2LMNAALDH1A1PKM
SCHEMBL13624235 0.79 KMT2A (0.38) MAPTGFERKDM4EGAASMN1; SMN2
SCHEMBL15260216 0.78 RAB9A (0.47) MAPTOPRM1OPRD1OPRK1SLC22A1
SCHEMBL2947757 0.77 MAPT (0.49) MAPTGAASMN1; SMN2LMNAALDH1A1
SCHEMBL2581059 0.77 MAPT (0.75) MAPTGFERKDM4EGAASMN1; SMN2
SCHEMBL15652017 0.76 LGMN (0.46) MAPTGFERKDM4EGAASMN1; SMN2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20090291945-A1 CYSTEINE PROTEASE INHIBITORS TEIJIN PHARMA LIMITED (JP) 2009-11-26 US disclosed
US-20090291945-A1 CYSTEINE PROTEASE INHIBITORS TEIJIN PHARMA LIMITED (JP) 2009-11-26 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090291945-A1 CYSTEINE PROTEASE INHIBITORS CTSE, SPINT2, CTSF MAPT 480/4885GFER 3552/4885KDM4E 4267/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.